Nuclear Factor-Kappa B in Gliomas as a Predictive Factor for Tumor Recurrence – A Clinicopathological Study

Basant H. Sayed; Samia M. Gabal; Ahmed M. Abdalaziz; Dalia Abd El-Kareem

doi:10.3889/oamjms.2023.11085

Authors

Basant H. Sayed Department of Pathology, Cairo University, Cairo, Egypt
Samia M. Gabal Department of Pathology, Cairo University, Cairo, Egypt
Ahmed M. Abdalaziz Department of Pathology, Cairo University, Cairo, Egypt
Dalia Abd El-Kareem Department of Pathology, Cairo University, Cairo, Egypt https://orcid.org/0000-0001-7838-7194

DOI:

https://doi.org/10.3889/oamjms.2023.11085

Keywords:

Gliomas, Glioblastoma, Nuclear Factor-Kappa B, Immunohistochemistry

Abstract

BACKGROUND: Glioma is the most common primary malignant brain tumor. Nuclear factor κB (NF-κB) has emerged as a regulator of the malignant phenotype in glioma, and in particular glioblastoma multiforme, with clear relation to tumor size, recurrence, and invasiveness.

AIM: The aim of the study was to study the analysis of NF-κB expression in gliomas of different histologic types and grades and its correlation with various clinicopathologic indicators.

METHODS: One hundred and ten paraffin blocks of glioma cases classified according to WHO classification into 14 (12.7%) cases of Grade I pilocytic astrocytoma, 27 (24.5%) cases of Grade II gliomas, 26 (23.6%) cases of Grade III gliomas, and 43 (39.1%) cases of Grade IV glioblastoma. The correlations between immunostainings and clinicopathological parameters were analyzed statistically.

RESULTS: Positive immunostaining for NF-κB was encountered in (64/110) 58.2% of gliomas. Statistical analysis revealed significant association between positive NF-κB expression and high histological grade (p < 0.001), recurrence of the tumors (p = 0.001), large tumor size (≥5 cm) (p < 0.001), histological subtypes (glioblastoma represented 51.6% of NF-κB positive cases, while pilocytic astrocytoma represented 1.6% of NF-κB positive cases) (p < 0.001) and age of the patient (≥40) (p = 0.039).

CONCLUSIONS: A strong direct relation between NF-κB expression and the grade of glioma was observed. NF-κB expression behaves as a negative independent prognostic factor for the risk of tumor recurrence. Hence, inhibition of NF-κB may be a new therapeutic strategy to prevent recurrence of gliomas, particularly the high-grade type.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Mostafizar M, Cortes-Pérez C, Snow W, Djordjevic J, Adlimoghaddam A, Albensi BC. Challenges with methods for detecting and studying the transcription factor nuclear factor kappa B (NF-κB) in the central nervous system. Cells. 2021;10(6):1335. https://doi.org/10.3390/cells10061335 PMid:34071243 DOI: https://doi.org/10.3390/cells10061335

Puliyappadamba VT, Hatanpaa KJ, Chakraborty S, Habib AA. The role of NF-κB in the pathogenesis of glioma. Mol Cell Oncol. 2014;1(3):e963478. https://doi.org/10.4161/23723548.2014.963478 PMid:27308348 DOI: https://doi.org/10.4161/23723548.2014.963478

Cahill KE, Morshed RA, Yamini B. Nuclear factor-κB in glioblastoma: Insights into regulators and targeted therapy. Neuro Oncol. 2015;18(3):329-39. https://doi.org/10.1093/neuonc/nov265 PMid:26534766 DOI: https://doi.org/10.1093/neuonc/nov265

Louis DN, Von Deimling A, Cavenee WK. Diffuse astrocytic and oligodendroglial tumours. In: WHO Classification of Tumours of the Central Nervous System. 4th ed. Lyon: International Agency for Research Centre; 2016. p. 15-56.

Moini J, Piran P. Functional and Clinical Neuroanatomy: A Guide for Health Care Professionals. Cambridge: Academic Press; 2020.

Johnson DR, Giannini C, Kaufmann TJ. Review of WHO 2016 Changes to Classification of Gliomas; Incorporation of Molecular Markers. In: Glioma Imaging. Cham: Springer; 2020. p. 127-38. DOI: https://doi.org/10.1007/978-3-030-27359-0_8

Barakat MK, Belal AM, Fadel SH, Gamal H. Outcome of high grade gliomas in limited resource country (10 years’ experience in Alexandria university oncology center 2003-2012). J Brain Tumors Neurooncol. 2016;1(111):2. https://doi.org/10.4172/2475-3203.1000111 DOI: https://doi.org/10.4172/2475-3203.1000111

Touati S, Djekkoun R, El-Okki ME, Satta D. Epidemiology and survival analyses of 333 adult glioma patients from Eastern Algeria (2008-2016). Afr Health Sci. 2020;20(3):1250-8. https://doi.org/10.4314/ahs.v20i3.29 PMid:33402972 DOI: https://doi.org/10.4314/ahs.v20i3.29

Li K, Lu D, Guo Y, Wang C, Liu X, Liu Y, et al. Trends and patterns of incidence of diffuse glioma in adults in the United States, 1973‐2014. Cancer Med. 2018;7(10):5281-90. https://doi.org/10.1002/cam4.1757 PMid:30175510 DOI: https://doi.org/10.1002/cam4.1757

Rasmussen BK, Hansen S, Laursen RJ, Kosteljanetz M, Schultz H, Nørgård BM, et al. Epidemiology of glioma: Clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the Danish neuro-oncology registry. J Neurooncol. 2017;135(3):571-9. https://doi.org/10.1007/s11060-017-2607-5 PMid:28861666 DOI: https://doi.org/10.1007/s11060-017-2607-5

Natukka T, Raitanen J, Haapasalo H, Auvinen A. Incidence trends of adult malignant brain tumors in Finland, 1990-2016. Acta Oncol. 2019;58(7):990-6. https://doi.org/10.1080/0284186X.2019.1603396 PMid:30985227 DOI: https://doi.org/10.1080/0284186X.2019.1603396

Silvaggi F, Silvani A, Lamperti EA, Leonardi M. Pathways of follow-up care in an Italian center: Retrospective study on patients with gliomas II and III. Neurol Sci. 2022;43(2):1303-10. https://doi.org/10.1007/s10072-021-05415-8 PMid:34235605 DOI: https://doi.org/10.1007/s10072-021-05415-8

Kurdi M, Butt NS, Baeesa S, Alghamdi B, Maghrabi Y, Bardeesi A, et al. Epidemiological distribution of primary central nervous system tumors in the Western Province of Saudi Arabia: A local registry from neuroscience-affiliated centers. Epidemiol Health. 2021;43:e2021037. https://doi.org/10.4178/epih.e2021037 PMid:34030435 DOI: https://doi.org/10.4178/epih.e2021037

Wang J, Hu G, Quan X. Analysis of the factors affecting the prognosis of glioma patients. Open Med (Wars). 2019;14(1):331-5. https://doi.org/10.1515/med-2019-0031 PMid:30997396 DOI: https://doi.org/10.1515/med-2019-0031

Alimohammadi E, Bagheri SR, Sadeghsalehi A, Rizevandi P, Rezaie Z, Abdi A. Prognostic factors in patients with glioblastoma multiforme: Focus on the pathologic variants. Acta Neurol Belg. 2020;120(6):1341-50. https://doi.org/10.1007/s13760-019-01171-x PMid:31222512 DOI: https://doi.org/10.1007/s13760-019-01171-x

Yang Y, Yao M, Long S, Xu C, Li L, Li Y, et al. Prognostic nomograms for primary high-grade glioma patients in adult: A retrospective study based on the SEER database. Biomed Res Int. 2020;2020:1346340. https://doi.org/10.1155/2020/1346340 PMid:32775408 DOI: https://doi.org/10.1155/2020/1346340

Hewedi I, Ibrahim R, Elserry T, Taha N, Mohamed H, Hassan M, et al. Frequency of primary central nervous system tumors in a tertiary hospital, Cairo, Egypt. J Community Health Manag. 2018;5(3):140-6. https://doi.org/10.18231/2394-2738.2018.0032 DOI: https://doi.org/10.18231/2394-2738.2018.0032